Quintiles Acquires Central American Research Organization

Quintiles Acquires Central American Research Organization

October 31, 2007

Bio-Trials to Complement Existing Quintiles Latin American
Organization

    RESEARCH TRIANGLE PARK, N.C., Oct. 31
/Xinhua-PRNewswire/ -- 

    Quintiles Transnational Corp. today announced that its
Latin American subsidiary has purchased Bio-Trials, a
leading Central American Clinical Research Organization
(CRO) with headquarters in Panama and offices in Costa
Rica, Guatemala, Ecuador and Peru.

    Bio-Trials provides clinical monitoring, clinical site
coordination, regulatory support, study management and
supply distribution services.  It has conducted about 30
clinical trials in 10 Central and South American countries,
and its customers have included a number of major
pharmaceutical companies and global CROs.

    "The acquisition of Bio-Trials gives Quintiles an
experienced, well-established team as well as access to an
experienced network of independent investigators in the
increasingly important Central American region," said
Jeff Thomis, President of Global Clinical Development
Services for Quintiles.  "Our customers are
increasingly including Central America as part of their
global drug development program.  The Bio-Trials team will
be a welcome addition to our Latin America group."

    In addition to its offices, Bio-Trials has supply
distribution points in Panama, Costa Rica, Guatemala and
Peru.  

    About Quintiles Latin America

    Quintiles Latin America was founded in 1995 and now has
nearly 600 employees in six countries, with headquarters in
Argentina, providing project management, clinical trial
monitoring, regulatory, drug safety, site management,
quality assurance, central laboratory and clinical trial
supplies services.  Quintiles Latin America has conducted
more than 300 studies involving more than 30,000 patients.

    About Quintiles Transnational

    Quintiles Transnational Corp. is powering the next
generation of healthcare by providing a broad range of
professional services in drug development, financial
partnering and commercialization for the pharmaceutical,
biotechnology and healthcare industries. With more than
19,000 employees and offices in more than 50 countries, it
is focused on providing customer-centric solutions that are
the gold standard of the industry. For more information,
please visit the company's Web site at http://www.qtrn.com.


    For more information, please contact:

     Dick Jones
     Media Relations
     Phone: [phone]
     Email: [e-mail]

     Greg Connors
     Investor Relations 
     Phone: [phone]
     Email: [e-mail]